Abionic
Abionic SA is a company specialized in the development of ultra-rapid "in vitro" diagnostic tests, located in Lausanne, Switzerland. Abionic has developed the abioSCOPE, a point-of-care diagnostic platform using its patented nanofluidic technology. The abioSCOPE is implemented in intensive care units and emergency departments to enable early identification of sepsis using a proprietary biomarker, Pancreatic Stone Protein (PSP). Secreted mainly by the pancreas and stomach, PSP rises rapidly in the blood in case of sepsis development and up to 72 hours before today's standard of care. Thus, this is a good and sensitive warning signal  to guide doctors in their decision to start antibiotic treatment. Besides the diagnostic value of PSP for sepsis, its availability at the bedside and the availability of the result in 5 minutes provides an additional opportunity to closely monitor patients at risk of developing sepsis. The abioSCOPE is also used in primary care for the screening of iron deficiency, respiratory allergies and more recently for COVID-19 screening with an antigenic saliva and nasopharyngeal test. History. Abionic was founded in 2010 at the Swiss Federal Institute of Technology in Lausanne (EPFL, École Polytechnique Fédérale de Lausanne) by Dr Nicolas Durand and  Dr Iwan Märki. Highlights of the company's development: 2012: 2014 : Fund-raising of 8.2 million Swiss francs in series B 2015: First prototype allergy panel ready 2016 : 2017 : 2018 : 2019 : 2020 : Start of the commercialisation of the abioSCOPE 2.0 2021 : 2022 : Increase of the tests portfolio with the development of D-Dimer (thrombosis) and CRP (inflammation) tests. Products. Abionic's solution is composed of the abioSCOPE, an "in vitro" diagnostic device and the consumable called the IVD CAPSULE, which is a single-use and analyte-specific tests. - Test principle : The test is based on mixing patient's sample (whole  blood, capillary, serum, saliva or nasopharyngeal sample) with a reagent containing fluorescent markers. The solution is then deposited on the capsule and enters nanochannels by capillary action. The volume-to-surface ratio then forces the molecules to interact immediately together, limiting their travel distance and reducing the incubation time to a few minutes. The concentration of the molecule of interest is then proportional to the intensity of the fluorescent signal measured by the abioSCOPE. - The different diagnostic tests developed by Abionic: Other tests are under development: D-Dimer, CRP, PCT.